[1]刘晓翰 黄刚 游月婷 徐俊波.心肌收缩力调节器治疗心力衰竭的机制及临床研究进展[J].心血管病学进展,2023,(9):790.[doi:10.16806/j.cnki.issn.1004-3934.2023.09.006]
 LIU Xiaohan,HUANG Gang,YOU Yueting,et al.Cardiac Contractility Modulation for Treatment of Heart Failure[J].Advances in Cardiovascular Diseases,2023,(9):790.[doi:10.16806/j.cnki.issn.1004-3934.2023.09.006]
点击复制

心肌收缩力调节器治疗心力衰竭的机制及临床研究进展()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年9期
页码:
790
栏目:
综述
出版日期:
2023-09-25

文章信息/Info

Title:
Cardiac Contractility Modulation for Treatment of Heart Failure
作者:
刘晓翰 黄刚 游月婷 徐俊波
(西南交通大学附属医院 成都市第三人民医院心内科 成都市心血管病研究所,四川 成都 610031)
Author(s):
LIU Xiaohan HUANG Gang YOU Yueting XU Junbo
(Department of Cardiology,The Affiliated Hospital of Southwest Jiaotong University,The Third People’s Hospital of Chengdu,Cardiovascular Disease Research Institute of Chengdu,Chengdu 610031,Sichuan,China)
关键词:
心力衰竭心肌收缩力调节器窄QRS波群
Keywords:
Heart failureCardiac contractility modulationNarrow QRS complex
DOI:
10.16806/j.cnki.issn.1004-3934.2023.09.006
摘要:
慢性心力衰竭(心衰)是各种心脏疾病的终末阶段。随着药物及器械治疗手段的不断进步,心衰患者病死率不断下降,患者预期寿命延长,生活质量逐步提高。心肌收缩力调节器在药物治疗的基础上,可降低窄QRS波群心衰患者的死亡率和再住院率、改善心衰症状、提高生活质量,或能成为窄QRS波群心衰患者的新选择。现对心肌收缩力调节器治疗慢性心衰的最新进展做一介绍。
Abstract:
Chronic heart failure is the terminal stage of various heart diseases. With the continuous improvement of drug and device treatment methods,the mortality of heart failure patients has continued to be decreased,followed by prolongation of the life expectancy and gradual improvement of quality of life. On the basis of drug treatment,cardiac contractility modulation can decrease the mortality and readmission rates of heart failure patients with narrow QRS complex,improve heart failure symptoms,and improve quality of life. They may become a new choice for heart failure patients with narrow QRS complex. This review aims to describe the advances of cardiac contractility modulation in chronic heart failure

参考文献/References:

[1].顾东风,黄广勇,吴锡桂,等. 中国心力衰竭流行病学调查及其患病率[J]. 中华心血管病杂志,2003,31(1):4.
[2].黄刚,邓晓奇,张小刚,等. 2020德国永久性心脏辅助装置植入者紧急医疗处置共识[J]. 心血管病学进展,2020,41(12):1353-1358.
[3].Pappone C,Vicedomini G,Salvati A,et al. Electrical modulation of cardiac contractility:clinical aspects in congestive heart failure[J]. Heart Fail Rev,2001,6(1):55-60.
[4].Cappannoli L,Scacciavillani R,Rocco E,et al. Cardiac contractility modulation for patient with refractory heart failure:an updated evidence-based review[J]. Heart Fail Rev,2021,26(2):227-235.
[5].Goliasch G,Khorsand A,Schütz M,et al. The effect of device-based cardiac contractility modulation therapy on myocardial efficiency and oxidative metabolism in patients with heart failure[J].?Eur J Nucl Med Mol Imaging,2012,39(3):408-415.
[6].Impulse Dynamics. OPTIMIZER? Smart Implantable Pulse Generator INSTRUCTIONS FOR USE[Z/OL]. (2020-11-13)[2022-03-08].https://impulse-dynamics.com/global/wp-content/uploads/sites/2/2020/11/13-290-008-EU-OPTIMIZER-Smart-IPG-IFU-ENG-Rev-09.pdf
[7].Lawo T,Borggrefe M,Butter C,et al. Electrical signals applied during the absolute refractory period:an investigational treatment for advanced heart failure in patients with normal QRS duration[J]. J Am Coll Cardiol,2005,46(12):2229-2236.
[8].Wood EH,Heppner RL,Weidmann S. Inotropic effects of electric currents.Ⅰ. Positive and negative effects of constant electric currents or current pulses applied during cardiac action potentials.Ⅱ. Hypotheses:calcium movements,excitation-contraction coupling and inotropic effects[J]. Circ Res,1969,24(3):409-445.
[9].Bouchard RA,Clark RB,Giles WR. Effects of action potential duration on excitation-contraction coupling in rat ventricular myocytes. Action potential voltage-clamp measurements[J]. Circ Res,1995,76(5):790-801.
[10].Mohri S,He KL,Dickstein M,et al. Cardiac contractility modulation by electric currents applied during the refractory period[J]. Am J Physiol Heart Circ Physiol,2002,282(5):H1642-H1647.
[11].Cannell MB,Kong CH. Local control in cardiac E-C coupling[J].?J Mol Cell Cardiol,2012,52(2):298-303.
[12].Brunckhorst CB,Shemer I,Mika Y,et al. Cardiac contractility modulation by non-excitatory currents:studies in isolated cardiac muscle[J]. Eur J Heart Fail,2006,8(1):7-15.
[13].Lyon AR,Samara MA,Feldman DS. Cardiac contractility modulation therapy in advanced systolic heart failure[J]. Nat Rev Cardiol,2013,10(10):584-598.
[14].Imai M,Rastogi S,Gupta RC,et al. Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure[J].?J Am Coll Cardiol,2007,49(21):2120-2128.
[15].Feaster TK,Casciola M,Narkar A,et al. Acute effects of cardiac contractility modulation on human induced pluripotent stem cell-derived cardiomyocytes[J].?Physiol Rep,2021,9(21):e15085.
[16].Roubertie F,Eschalier R,Zemmoura A,et al. Cardiac contractility modulation in a model of repaired tetralogy of Fallot:a sheep model[J].?Pediatr Cardiol,2016,37(5):826-833.
[17].Tsch?pe C,Kherad B,Klein O,et al. Cardiac contractility modulation:mechanisms of action in heart failure with reduced ejection fraction and beyond[J]. Eur J Heart Fail,2019,21(1):14-22.
[18].Ning B,Zhang F,Song X,et al. Cardiac contractility modulation attenuates structural and electrical remodeling in a chronic heart failure rabbit model[J].?J Int Med Res,2020,48(10):300060520962910.
[19].Hao Q,Zhang F,Wang Y,et al. Cardiac contractility modulation attenuates chronic heart failure in a rabbit model via the PI3K/AKT pathway[J].?Biomed Res Int,2020,2020:1625362.
[20].Chen H,Liu S,Zhao C,et al. Cardiac contractility modulation improves left ventricular systolic function partially via miR-25 mediated SERCA2A expression in rabbit trans aortic constriction heart failure model [J].?J Thorac Dis,201810(6):3899-3908.
[21].Butter C,Rastogi S,Minden HH,et al. Cardiac contractility modulation electrical signals improve myocardial gene expression in patients with heart failure[J]. J Am Coll Cardiol,2008,51(18):1784-1789.
[22].Neelagaru SB,Sanchez JE,Lau SK,et al. Nonexcitatory,cardiac contractility modulation electrical impulses:feasibility study for advanced heart failure in patients with normal QRS duration[J]. Heart Rhythm,2006,3(10):1140-1147.
[23].Borggrefe MM,Lawo T,Butter C,et al. Randomized,double blind study of non-excitatory,cardiac contractility modulation electrical impulses for symptomatic heart failure[J]. Eur Heart J,2008,29(8):1019-1028.
[24].Kadish A,Nademanee K,Volosin K,et al. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure[J]. Am Heart J,2011,161(2):329-337.e1-2.
[25].Abraham WT,Nademanee K,Volosin K,et al. Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure[J]. J Card Fail,2011,17(9):710-717.
[26].Kuschyk J,Roeger S,Schneider R,et al. Efficacy and survival in patients with cardiac contractility modulation:long-term single center experience in 81 patients[J]. Int J Cardiol,2015,183:76-81.
[27].Liu M,Fang F,Luo XX,et al. Improvement of long-term survival by cardiac contractility modulation in heart failure patients:a case-control study[J]. Int J Cardiol ,2016,206:122-126.
[28].R?ger S,Rudic B,Akin I,et al. Long-term results of combined cardiac contractility modulation and subcutaneous defibrillator therapy in patients with heart failure and reduced ejection fraction[J]. Clin Cardiol,2018,41(4):518-524.
[29].Abraham WT,Kuck KH,Goldsmith RL,et al. A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation[J]. JACC Heart Fail,2018,6(10):874-883.
[30].Anker SD,Borggrefe M,Neuser H,et al. Cardiac contractility modulation improves long-term survival and hospitalizations in heart failure with reduced ejection fraction[J]. Eur J Heart Fail,2019,21(9):1103-1113.
[31].Wiegn P,Chan R,Jost C,et al. Safety,performance,and efficacy of cardiac contractility modulation delivered by the 2-lead Optimizer S mart system:the FIX-HF-5C2 study[J]. Circ Heart Fail,2020,13(4):e006512.
[32].Kuschyk J,Falk P,Demming T,et al. Long-term clinical experience with cardiac contractility modulation therapy delivered by the Optimizer Smart system[J]. Eur J Heart Fail,2021,23(7):1160-1169.
[33].Fastner C,Yuecel G,Rudic B,et al. Cardiac contractility modulation in patients with ischemic versus non-ischemic cardiomyopathy:results from the MAINTAINED observational study[J]. Int J Cardiol,2021,342:49-55.
[34].Linde C,Grabowski M,Ponikowski P,et al. Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction:a pilot study(CCM-HFpEF)[J]. Eur J Heart Fail,2022,24(12):2275-2284.
[35].Dulai R,Chilmeran A,Hassan M,et al. How many patients with heart failure are eligible for cardiac contractility modulation therapy?[J].?Int J Clin Pract,2021,75(1):e13646.
[36].中华医学会心电生理和起搏分会,中国医师协会心律学专业委员会. 植入型心律转复除颤器临床应用中国专家共识(2021)[J] . 中华心律失常学杂志,2021,25(4):280-299.
[37].R?ger S,Schneider R,Rudic B,et al. Cardiac contractility modulation:first experience in heart failure patients with reduced ejection fraction and permanent atrial fibrillation[J]. Europace,2014,16(8):1205-1209.

相似文献/References:

[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
 DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(9):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
 LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(9):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
 ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(9):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
 LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(9):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
 KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(9):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
 SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(9):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
 XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(9):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
 GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(9):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
 HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(9):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
 WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(9):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]

备注/Memo

备注/Memo:
图1 CCM电刺激与临床研究植入策略示意图[4
更新日期/Last Update: 2023-10-17